Insight Molecular Diagnostics (NASDAQ:IMDX) Stock: Insider Broadwood Partners, L.P. Purchases 3,428,571 Shares

Insight Molecular Diagnostics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Broadwood Partners bought 3,428,571 IMDX shares at an average $1.75 per share, for about $6 million. The purchase increased its stake by 27.03% to 16,113,455 shares.
  • IMDX shares traded at $1.65 on Thursday, within a 12-month range of $1.50 to $7.51. The company reported quarterly EPS of -$0.19 and revenue of $0.56 million.
  • Analyst views are mixed, with two Buy, two Hold, and one Sell rating; MarketBeat’s consensus rating is Hold, with an $8.33 target price.
  • Five stocks to consider instead of Insight Molecular Diagnostics.

Insight Molecular Diagnostics Inc. (NASDAQ:IMDX - Get Free Report) major shareholder Broadwood Partners, L.P. acquired 3,428,571 shares of the firm's stock in a transaction on Tuesday, November 17th. The shares were bought at an average cost of $1.75 per share, with a total value of $5,999,999.25. Following the completion of the acquisition, the insider directly owned 16,113,455 shares in the company, valued at approximately $28,198,546.25. This represents a 27.03% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC.

Insight Molecular Diagnostics Price Performance

Shares of IMDX stock traded up $0.06 during trading hours on Thursday, reaching $1.65. The company had a trading volume of 168,606 shares, compared to its average volume of 237,924. Insight Molecular Diagnostics Inc. has a 12 month low of $1.50 and a 12 month high of $7.51. The business has a fifty day simple moving average of $3.15 and a 200-day simple moving average of $4.48. The company has a market cap of $54.09 million, a price-to-earnings ratio of -1.32 and a beta of 1.90.

Insight Molecular Diagnostics (NASDAQ:IMDX - Get Free Report) last announced its quarterly earnings results on Monday, November 16th. The company reported ($0.19) earnings per share (EPS) for the quarter. The company had revenue of $0.56 million during the quarter.

Analyst Ratings Changes

Several analysts have recently commented on IMDX shares. Needham & Company LLC reiterated a "buy" rating and issued a $9.00 target price on shares of Insight Molecular Diagnostics in a report on Tuesday, August 18th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Insight Molecular Diagnostics in a research report on Monday, September 21st. Wall Street Zen lowered shares of Insight Molecular Diagnostics from a "hold" rating to a "sell" rating in a research note on Saturday, October 3rd. BTIG Research reissued a "neutral" rating on shares of Insight Molecular Diagnostics in a research report on Wednesday. Finally, Stephens restated an "equal weight" rating and issued a $4.00 target price on shares of Insight Molecular Diagnostics in a research note on Wednesday. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Insight Molecular Diagnostics has an average rating of "Hold" and a consensus target price of $8.33.

Read Our Latest Stock Analysis on IMDX

About Insight Molecular Diagnostics

(Get Free Report)

Oncocyte Corporation, now known as Insight Molecular Diagnostics, Inc. NASDAQ: IMDX, is a molecular diagnostics company focused on monitoring organ transplants. Its tests analyze donor-derived cell-free DNA in a transplant recipient's blood to help assess graft health and identify signs of potential injury or rejection. The company's VitaGraft tests include assays for kidney and liver transplant monitoring. These laboratory-developed tests are processed through the company's clinical laboratory and are intended to provide clinicians with information that can complement other aspects of post-transplant care.

Featured Articles

Insider Buying and Selling by Quarter for Insight Molecular Diagnostics (NASDAQ:IMDX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Insight Molecular Diagnostics Right Now?

Before you consider Insight Molecular Diagnostics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insight Molecular Diagnostics wasn't on the list.

While Insight Molecular Diagnostics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines